Cargando…

Antibody-Drug Conjugates in Bladder Cancer

Urothelial carcinoma (UC) is characterized by expression of a plethora of cell surface antigens, thus offering opportunities for specific therapeutic targeting with use of antibody-drug conjugates (ADCs). ADCs are structured from two major constituents, a monoclonal antibody (mAb) against a specific...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vlachostergios, Panagiotis J., Jakubowski, Christopher D., Niaz, Muhammad J., Lee, Aileen, Thomas, Charlene, Hackett, Amy L., Patel, Priyanka, Rashid, Naureen, Tagawa, Scott T.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	IOS Press 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087439/ https://www.ncbi.nlm.nih.gov/pubmed/30112436 http://dx.doi.org/10.3233/BLC-180169

Ejemplares similares

Trimodality therapy in variant urothelial carcinoma: choose wisely
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2017)

Prostate-specific Membrane Antigen Based Antibody-drug Conjugates for Metastatic Castration-resistance Prostate Cancer
por: Niaz, Muhammad O, et al.
Publicado: (2020)

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy
por: Klute, Kelsey, et al.
Publicado: (2014)

Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer
por: Vlachostergios, Panagiotis J., et al.
Publicado: (2021)

A novel strategy for treatment of bladder cancer: Antibody-drug conjugates
por: Kim, Jung Hoon, et al.
Publicado: (2022)

An overview of antibody–drug conjugates in oncological practice
por: Theocharopoulos, Charalampos, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Hafeez, Umbreen, et al.
Publicado: (2020)

Antibody–Drug Conjugates for Cancer Therapy
por: Parslow, Adam C., et al.
Publicado: (2016)

Antibody-Oligonucleotide Conjugates: A Twist to Antibody-Drug Conjugates
por: Dugal-Tessier, Julien, et al.
Publicado: (2021)

Methods for site-specific drug conjugation to antibodies
por: Behrens, Christopher R, et al.
Publicado: (2014)

Antibody-Drug Conjugates: Functional Principles and Applications in Oncology and Beyond
por: Theocharopoulos, Charalampos, et al.
Publicado: (2021)

Introduction to Antibody-Drug Conjugates
por: Pettinato, Mark C.
Publicado: (2021)

ANTIBODY DRUG CONJUGATES (ADCS)
por: Terpos, E.
Publicado: (2023)

Monoclonal Antibodies and Antibody Drug Conjugates in Multiple Myeloma
por: Radocha, Jakub, et al.
Publicado: (2021)

Advances in preclinical evaluation of experimental antibody-drug conjugates
por: Lyons, Scott K., et al.
Publicado: (2021)

Antibody Drug Conjugates in Glioblastoma – Is There a Future for Them?
por: Parakh, Sagun, et al.
Publicado: (2021)

Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs)
por: Hoffmann, Ricarda M., et al.
Publicado: (2020)

Antibody-Drug Conjugates Used in Breast Cancers
por: Abbas, Aram J., et al.
Publicado: (2021)

Antibody-drug conjugates: recent advances in conjugation and linker chemistries
por: Tsuchikama, Kyoji, et al.
Publicado: (2016)

Pyrrolobenzodiazepine Antibody-Drug Conjugates Designed for Stable Thiol Conjugation
por: Christie, R. James, et al.
Publicado: (2017)

Methods to Make Homogenous Antibody Drug Conjugates
por: Kline, Toni, et al.
Publicado: (2014)

Sulfatase-cleavable linkers for antibody-drug conjugates
por: Bargh, Jonathan D., et al.
Publicado: (2020)

Resistance to Pembrolizumab and Axitinib in Renal Cell Carcinoma: Clinical and Genomic Evaluation
por: Vlachostergios, Panagiotis J.
Publicado: (2020)

Loss of tumor suppressive properties of lipid metabolism enzyme CPT2 in ovarian carcinoma: Comment on “CPT2 down-regulation promotes tumor growth and metastasis through inducing ROS/NFκB pathway in ovarian cancer” by Zhang et al.
por: Vlachostergios, Panagiotis J.
Publicado: (2021)

Combined DNA repair defects in testicular metastasis from prostate cancer sensitize to immune checkpoint blockade
por: Vlachostergios, Panagiotis J.
Publicado: (2021)

The interplay of cell cycle and DNA repair gene alterations in upper tract urothelial carcinoma: predictive and prognostic implications
por: Vlachostergios, Panagiotis J
Publicado: (2020)

Antibody-Drug Conjugates: Possibilities and Challenges
por: Nejadmoghaddam, Mohammad-Reza, et al.
Publicado: (2019)

Acquired Resistance to Antibody-Drug Conjugates
por: Collins, Denis M., et al.
Publicado: (2019)

Antibody–Drug Conjugates: The Last Decade
por: Joubert, Nicolas, et al.
Publicado: (2020)

Antibody-drug conjugates: Present and future
por: Beck, Alain, et al.
Publicado: (2013)

Antibody–Drug Conjugate to Treat Meningiomas
por: Chen, Kai, et al.
Publicado: (2021)

Clinical Pharmacology of Antibody-Drug Conjugates
por: Mahmood, Iftekhar
Publicado: (2021)

Mechanisms of Resistance to Antibody–Drug Conjugates
por: Abelman, Rachel Occhiogrosso, et al.
Publicado: (2023)

Mechanisms of Resistance to Antibody-Drug Conjugates
por: Khoury, Rita, et al.
Publicado: (2023)

Peroxide-cleavable linkers for antibody–drug conjugates
por: Ashman, Nicola, et al.
Publicado: (2023)

Recent advances of antibody drug conjugates for clinical applications
por: Zhao, Pengxuan, et al.
Publicado: (2020)

Antibody-Drug Conjugates: The New Frontier of Chemotherapy
por: Ponziani, Sara, et al.
Publicado: (2020)

Considerations for the Nonclinical Safety Evaluation of Antibody–Drug Conjugates
por: Fisher, J. Edward
Publicado: (2021)

Synthesis and Evaluation of Camptothecin Antibody–Drug Conjugates
por: Li, Wei, et al.
Publicado: (2019)

Extracellular Antibody Drug Conjugates Exploiting the Proximity of Two Proteins
por: Marshall, David J, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_jpf058ku8m77hub3bvluct7bpv